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Peroxovanadium compounds are potent insulinomimetic agents and protein tyrosine phospha-
tase inhibitors. In this study, the potential toxicity of peroxovanadium complex bpV(phen) on
rat pheochromocytoma PC12 cells was examined, and the mechanism by which this compound
influences cell survival and/or death was explored. BpV(phen) exerted a bimodal effect on PC12
cells: survival-enhancing effect at lower and death-inducing effect at higher micromolar con-
centrations. 1 and 3 mol dm–3 bpV(phen) intensely induced ERK activation. In contrast, 10
and 100 mol dm–3 bpV(phen) stimulated strong and sustained JNK and p38 MAPK activation
as well as caspase-3 activation that preceded bpV(phen)-induced apoptotic cell death. It is sug-
gested that bpV(phen) might exert its action on PC12 cell survival by modulation of MAPKs
and caspase-3 activation.
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INTRODUCTION
Vanadium is a dietary trace element suggested to be es-
sential for higher animals. In the late 1970s and the early
1980s, it was demonstrated that vanadate (V5+) solutions
produce insulin-like effects in rat diaphragms and isolat-
ed adipocytes in vitro.1 In the following years, the insu-
linomimetic actions of vanadium salts were examined in
a large variety of insulin-responsive cells and tissues and
it turned out that they mimic most of the known meta-
bolic effects of insulin. Vanadium salts activated hexose
transport in adipose and muscle tissues, activated glyco-
genesis and inhibited glycogenolysis in liver.2 Hepatic
gluconeogenesis was suppressed by lowering the phos-
phoenolpyruvate carboxykinase (PEPCK) mRNA levels3
and by inhibition of glucose-6-phosphatase activity,4 an
event that can also account for the ability of vanadate to
arrest glycogen breakdown. Glycolysis in liver was en-
hanced due to the vanadate-mediated inhibition of fruc-
tose 2,6-bisphosphatase5 and induction of the L-type py-
ruvate kinase gene.6 Thus, vanadate inhibits several key
metabolic enzyme systems in liver, muscle and adipose
tissue, all of which act collectively towards utilizing or
storing cell-entered glucose, as well as blocking the ef-
fects of hormones that oppose insulin action.
Peroxovanadium compounds are a powerful class of
insulinomimetic agents that were discovered when the
two insulin-like agents, vanadate and hydrogen peroxide
(H2O2), were combined and found to be synergistic in their
activities to produce insulin-like effects. Peroxovanadium
compounds resemble the phosphate structure, similar to
vanadate species, but the addition of peroxo group(s) se-
quentially increases their potency as protein tyrosine
phosphatase (PTP) inhibitors, presumably by increasing
their abilities to irreversibly oxidize the bound tiols.7,8
Most data support the inhibition of PTPs and the re-
sultant indirect stimulation of tyrosine phosphorylation
as the mechanism by which vanadium compounds pro-
mote their insulin-like effects.9 Although one might sus-
pect that the insulin receptor is involved, the latest stud-
ies indicate that the molecular basis of insulinomimetic
effects of vanadium or vanadium salts does not involve
the insulin receptor tyrosine kinase activity and the sub-
sequent phosphorylation of insulin receptor substrate-1
(IRS-1), but that vanadium salts activate phosphatidyl-
inositol 3-kinase (PI3-K) and mitogen-activated protein
kinases (MAPKs).10–12
MAPKs are important components in the intracellu-
lar regulatory network that transduce extracellular signals
to intracellular responses. There are currently four major
classes of MAPKs, including extracellular signal-regulated
kinase 1/2 (ERK1/2), c-Jun N-terminal kinase/stress-ac-
tivated protein kinase (JNK/SAPK), p38 MAPK, and big
MAPK (BMK)/ERK5. The functions of ERK3 and
ERK7, as well as of the recently identified ERK8, are
less understood.13 A common feature for activation of all
MAPK isoforms is the requirement for phosphorylation
of both a threonine and a neighbouring tyrosine regula-
tory site by a specific upstream protein kinase.14 Once
activated, MAPKs phosphorylate other cytoplasmic pro-
teins and translocate from the cytoplasm to the nucleus
to regulate the activity of transcription factors, thus mo-
dulating expression of different genes. MAPK cascades
participate in a diverse array of cellular programs, in-
cluding cell motility, cell division, proliferation, differ-
entiation, cell survival, and cell death.13,15,16
In mammalian cells, the sophisticated interplay be-
tween factors that promote or suppress apoptotic cell
death results in a complicated regulatory network, which
determines the fate of an individual cell as part of its
multicellular environment. Members of caspase family
are activated in most scenarios of apoptosis. Caspases
specifically cleave their substrates after aspartic acid resi-
dues and the activity of these proteases depends on the
critical cysteine residue within a highly conserved ac-
tive-site pentapeptide QACRG. In the cell, caspases are
synthesized as inactive zymogens, the so called procas-
pases. So far, 14 different members of this family have
been described in mammals, with caspase-11 and caspa-
se-12 only identified in the mouse.17,18 Because they
bring about most of the visible changes that characterize
apoptotic cell death, caspases can be thought of as the
central executioners of the apoptotic pathway.19
The aim of the present study was to examine the po-
tential toxicity of peroxovanadium complex potassium bis-
peroxo(1,10-phenanthroline)oxovanadate (V) bpV(phen)
on rat pheochromocytoma PC12 cells, as well as to ex-
plore the mechanism by which this compound influences
cell survival and/or cell death.
EXPERIMENTAL
Cell Culture
Rat pheochromocytoma PC12 cells20 were cultured at 37
°C in a 5 % CO2 atmosphere in RPMI 1640 medium sup-
plemented with 10 % heat-inactivated foetal bovine serum
(FBS), 100 IU/ml (60 g/ml) penicillin, 100 g/ml strep-
tomycin, 2.5 g/ml amphotericin B, 290 g/ml L-glutamine
and 2.5 mg/ml sodium hydrogen carbonate. Cells were plat-
ed in 6 or 24 well plates, usually at a plating density from
105–106 cells/ml.
Treatment
After 24 h preincubation, PC12 cells were treated with 1, 3,
10 and 100 mol dm–3 bpV(phen) for 5, 12, 24 or 48 hours.
BpV(phen) was provided courtesy of Dr Alan Shaver (De-
partment of Chemistry, McGill University, Montreal, Can-
ada). Stock solution (10 mmol dm–3) was prepared by dis-
solving bpV(phen) in a phosphate buffered solution (PBS)
and protected from light.
MTT Colorimetric Assay
PC12 cells were plated in 24 well plates and treated with
bpV(phen) for 24 and 48 hours. At the end of the treatment,
cells were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) for 4 hours at 37 °C in
a humidified atmosphere of 95 % air and 5 % CO2. Cells
were washed twice with PBS, pH = 7.4, and DMSO was
added to each well. After 20 minutes, cells were centrifug-
ed at 4 °C at 14000 rpm. The absorbance was measured at
595 nm using a microplate reader.
Lactate Dehydrogenase (LDH) Assay
50 l of culture supernatant was assayed, using 2 ml of
working reagent (61.43 mmol dm–3 Tris buffer, 0.20 mmol
dm–3 NADH, pH = 7.4) and 10 l of substrate (21.5 mmol
dm–3 pyruvate). Absorbances were measured at 339 nm ev-
ery 30 s over a 5-min time period on Pye-Unicam SP8-100
UV/Vis spectrophotometer, and the LDH activity in mol
min–1 dm–3 was calculated.21
Nuclear Staining
Chromatin integrity was examined by staining PC12 cells
with Hoechst 33258 (2-2-(4-hydroxyphenyl)-6-benzimida-
zole-6-(1-methyl-4-piperazyl)-benzimidazole-trihydrochloride;
bisbenzimide) at a concentration of 1 g/ml in PBS for 15
min. After rinsing with PBS, chromatin condensation in
300 cells was examined by fluorescence microscopy (Olympus
BX50), magnification 1000x.
420 L. RUMORA et al.
Croat. Chem. Acta 78 (3) 419¿425 (2005)
Whole Cell Lysis
Treated and untreated PC12 cells were washed twice with
cold PBS and lysed with 100 L of ice-cold whole-cell lysis
buffer (50 mmol dm–3 Tris-HCl pH = 8.0, 137 mmol dm–3
NaCl, 1 % Nonident P-40, 10 % glycerol, and »Complete
protease inhibitor« cocktail tablet). After 20 minutes, cell
lysates were subsequently centrifuged at 4 °C at 14000 rpm
and the total protein content was determined by the method
of Lowry with bovine serum albumin as the protein stan-
dard.22 Samples were denatured by boiling for 3 minutes
with 6x Laemmli sample buffer (0.375 M Tris-HCl pH =
6.8, 12 g/100 ml SDS, 3 % glycerol, 0.2 g/100 ml bro-
mophenol blue, 12 % -mercaptoethanol in distilled water).
Western Blotting
35 g of total proteins were loaded for each sample onto a
12 % polyacrylamide gel, usually run at 100 V. Transfer
onto nitrocellulose membrane was conducted at 250 mA for
90 minutes. Membranes were blocked for one hour with
blocking buffer containing 1 g/100 ml BSA and 1 g/100 ml
chicken egg albumin in TBS+T (25 mmol dm–3 Tris pH =
7.6, 150 mmol dm–3 NaCl, 0.05 % Tween 20). Membranes
were probed overnight at 4 °C with anti-JNK-P antibody
(Promega) diluted 1:5000 in blocking buffer, anti-ERK-P
antibody (Promega) diluted 1:5000 in blocking buffer, anti-
p38-P antibody (Promega) diluted 1:2000 in blocking buf-
fer, anti-JNK1(FL) antibody (Santa Cruz Biotechnology)
diluted 1:800 in blocking buffer, anti-ERK1(C-16) antibody
(Santa Cruz Biotechnology) diluted 1:1000 in blocking buf-
fer, anti-p38(C-20) antibody (Santa Cruz Biotechnology)
diluted 1:1000 in blocking buffer, or anti-caspase-3(H-277)
antibody (Santa Cruz Biotechnology) diluted 1:200 in block-
ing buffer. A horseradish peroxidase-conjugated secondary
antibody (Amersham Biosciences) diluted 1:4000 in 5 g/100
ml low fat milk in TBS+T was utilized to allow detection
of the appropriate bands using enhanced chemiluminescen-
ce reagent (ECLTM Western Blotting Detection Reagents,
Amersham Biosciences) and film (X-OMAT Blue film, Ko-
dak). Membranes were stripped by incubation at 65 °C for
half an hour in stripping buffer (100 mmol dm–3 -mercap-
toethanol, 2 g/100 ml SDS and 62.5 mmol dm–3 Tris-HCl
pH = 6.7). For MAPKs, stripping was done separately for
each antigen after the analysis of unphosphorylated protein.
All experiments were conducted at least three times and
representative blots were analyzed using ScionImage soft-
ware for Windows (Scion Corporation).
Statistical Analysis
Data were analyzed by a one-way analysis of variance
(ANOVA) followed by a multiple comparison procedure
(Dunnett’s test). The level of P<0.05 was considered statis-
tically significant for all tests performed. We also perform-
ed Levene’s test and established homogeneity of variance
among all the groups of data assessed. The SPSS computer
program for MS Windows, release 6.0, was used for statis-
tical analysis.
RESULTS
Effect of bpV(phen) on PC12 Cell Survival
PC12 cells were treated with 1, 3, 10 and 100 mol dm–3
bpV(phen) in order to assess bpV(phen) toxicity and de-
termine the mode of cell death. Cell viability was evalu-
ated at 24 and 48 hours by three different assays: MTT
colorimetric assay was used in order to assess cellular
reducing potential (Figure 1a), LDH assay was applied
to monitor cellular membrane integrity (Figure 1b) and
Hoechst 33258 staining was employed to observe nucle-
ar chromatin integrity (Figure 2).
BpV(phen) cytotoxicity, as measured by different
criteria, was concentration-dependent. Both 1 mol dm–3
and 3 mol dm–3 bpV(phen) induced PC12 cell metabo-
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Figure 1. Effects of bpV(phen) on PC12 cell viability. Cells were
treated with 1, 3, 10 and 100 mol dm–3 bpV(phen). Cell viability
was examined at 24 h and 48 h by MTT reduction assay (a) and
LDH release assay (b). Values for untreated control cells were ta-
ken as 100 % and values for bpV(phen)-treated cells were taken
as the increase and decrease in MTT reduction (a) or increase in
LDH release (b), compared to controls. Data represent the mean
+ SD of six replicates for each experimental condition. Significant-
ly different from control values, *P<0.05.
lic activity, especially at 48 h (Figure 1a). No statisti-
cally significant LDH leakage (Figure 1b) or changes of
PC12 cells chromatin integrity (Figure 2) could be de-
tected after treatment with lower micromolar bpV(phen)
concentrations, as compared to untreated control cells.
In contrast, 10 mol dm–3 and 100 mol dm–3 bpV(phen)
caused a high inhibition of mitochondrial function and
provoked LDH release (Figure 1) after 24 h and even
more so after 48 h of treatment. Thus, a decline in cellular
metabolic activity occurred before a breakdown of mem-
brane integrity in PC12 cells treated with higher micro-
molar bpV(phen) concentrations, which is consistent with
apoptotic cell death. Furthermore, the same treatment
caused chromatin condensation, one of the hallmarks of
apoptotic process (Figure 2). Some necrotic cells were
observed after incubation with 10 and 100 mol dm–3
bpV(phen). This is in agreement with increased LDH re-
lease that could occur due to necrotic cell death or, in a
later stage, of apoptosis due to increased permeability of
the cell membrane.
BpV(phen) Modulates MAPKs and Caspase-3
Activation
In order to explore the mechanism by which bpV(phen)
influences PC12 cell survival and death, we examined
MAPKs expression and activation, and procaspase-3 ex-
pression by the Western blot analysis after 5, 12 and 24
hours of treatment.
The level of expression of all three MAPKs was not
altered by bpV(phen) (data not shown). However, this
compound modulated MAPKs activation (Figure 3). ERK
phosphorylation was stimulated in cells treated with 1
and 3 mol dm–3 bpV(phen) for 5 h and 12 h, and no
phospho-JNK or phospho-p38 signal was observed at
the same time points examined. In contrast, both 10 mol
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Figure 2. Induction of apoptosis by bpV(phen). PC12 cells were
treated with 1, 3, 10 and 100 mol dm–3 bpV(phen) for 24 h and
48 h. Cells were stained with Hoechst 33258 dye and quantifica-
tion of nuclei with condensed, intensively stained chromatin was
performed. Data represent the mean + SD of the number of apop-
totic cells in 100 cells examined for each experimental condition.
Significantly different from control values, *P<0.05.
Figure 3. BpV(phen) provokes a concentration-dependent activa-
tion of MAPKs. PC12 cells were exposed to 1, 3, 10 and 100
mol dm–3 bpV(phen) for 5 (a), 12 (b) and 24 (c) hours. Western
blot analysis was performed as described in the Experimental sec-
tion. Representative blots for activation of ERK, JNK and p38
MAPK from three independent experiments are shown.
Figure 4. Activation of caspase-3 by bpV(phen). PC12 cells were
treated with 1, 3, 10 and 100 mol dm–3 bpV(phen) for 5 (a), 12 (b)
and 24 (c) hours. Western blot analysis, using anti-caspase-3(H-
277) antibody, was performed. Representative blots for procas-
pase-3 expression from three independent experiments are shown.
dm–3 and 100 mol dm–3 bpV(phen) induced strong and
sustained JNK and p38 MAPK activation that could be
detected even after 24 h of treatment.
Next, we addressed the question whether the activa-
tion of caspase machinery might play a role in mediating
PC12 cell death stimulated by higher micromolar bpV(phen)
concentrations. 10 and 100 mol dm–3 bpV(phen) stimu-
lated proteolytic processing of procaspase-3 at 12 and 24
h (Figure 4), as shown by decreasing intensity of the
procaspase-3 band, suggesting that caspase-3 is activat-
ed during the course of bpV(phen)-induced apoptosis.
DISCUSSION
Peroxovanadium compounds are potent insulinomimetic
agents and protein tyrosine phosphatase (PTP) inhibi-
tors. In mammals, each cell is simultaneously exposed to
multiple signals and must integrate these inputs to cho-
ose an appropriate response. By altering the net phos-
phorylation status of the cell, peroxovanadium complex-
es could influence cell survival, and the final outcome
depends on the cellular context, type of the compound
and ancillary ligand within its structure, treatment dura-
tion and concentration of the compound used for the treat-
ment.1,23
Differentiation of PC12 cells has been observed fol-
lowing incubation with sodium orthovanadate.24 Fur-
thermore, vanadate exhibits mitogenic properties in SV40-
transformed cells.25 In C3H10T1/3 mouse fibroblasts,
peroxovanadates formed in situ have been found to lead
to proliferation.26 However, vanadium compounds can
also exhibit cytotoxic and antineoplastic effects both in
vitro and in vivo.1,27,28
It was shown earlier that vanadium compounds could
exert a bimodal effect on cells: survival-enhancing effect
at lower and death-inducing effect at higher micromolar
concentrations,29–31 which is in agreement with the re-
sults presented in this study. We demonstrated that 1 and
3 mol dm–3 bpV(phen) stimulate PC12 cell metabolic
activity. However, 10 and 100 mol dm–3 bpV(phen)
caused a high inhibition of mitochondrial function and
induced apoptotic cell death.
Vanadate may enhance tyrosine phosphorylation of
various endogenous cellular proteins and/or activation of
signaling molecules such as mitogen-activated protein
kinases (MAPKs). This family includes extracellular sig-
nal-regulated kinases (ERKs) that have been linked to
cell survival, as well as stress kinases, c-Jun N-terminal
kinases (JNKs) and p38 MAPKs, which generally pro-
mote inhibition of cell growth and induce apoptosis. This
dichotomy, however, is an oversimplification, and the
actual roles of each MAPK cascade are highly cell type
and context dependent.15 ERK and JNK/p38 cascade may
have opposing effects in differentiated PC12 cells after
NGF-withdrawal, and a dynamic balance between the anti-
apoptotic ERK pathway and the pro-apoptotic JNK/p38
MAPK pathways appears to be important to determine
whether a cell survives or undergoes apoptosis.32 In this
study, we hypothesized that bpV(phen) might exert its
action on PC12 cell survival by modulation of MAPKs
and/or caspase-3 activation. Lower micromolar bpV(phen)
concentrations intensely induced ERK activation, and
higher micromolar bpV(phen) concentrations stimulated
strong and sustained JNK and p38 MAPK activation. A
similar pattern of MAPKs phosphorylation was detected
in rat insulinoma RINm5F cells after bpV(phen) treat-
ment.33 Temporal organization of MAPK activities can
play an important role in the generation of specific bio-
logical responses. It was demonstrated in PC12 cells that
the duration of ERK activation is critical for cellular re-
sponses, because transient activation induced cell prolife-
ration and sustained activation caused cell differentia-
tion.34 Sustained ERK activation is associated with ERK
nuclear translocation35,36 and phosphorylation of tran-
scription factors. Therefore, in contrast to transient acti-
vation, sustained activation might have a different effect
on gene expression.34 It has also been reported that dura-
tion of JNK activation is a decisive factor for determining
cell fate, with transient activation leading to cell prolife-
ration or differentiation, and prolonged JNK activation
causing apoptosis.37–39 Sustained activation of JNK and
p38 MAPK has been shown to precede apoptosis of
PC12 cells induced by withdrawal of trophic factors.40
Our results seem to support this notion, since strong and
sustained JNK and p38 phosphorylation preceded bpV-
(phen)-induced PC12 cell apoptosis. 10 and 100 mol
dm–3 bpV(phen) also stimulated cleavage of procaspase-3,
suggesting that caspase-3 is activated during the apop-
totic process. Caspase-3 activation is one of the hall-
marks and commitment steps of programmed cell death.
In lymphoid cell lines, pervanadate treatment caused ac-
tivation of caspases-3, -8 and -9, induction of mitochon-
drial permeability transition, release of cytochrome c and
DNA fragmentation.41 The interplay between MAPKs
and the caspase machinery in the induction of apoptosis
was demonstrated previously. It was suggested that JNK
signaling plays a major role in activation of the caspase-
8 pathway that accounts for vanadate-induced apoptosis
of cerebellar granule progenitors.42 In our study, activa-
tion of stress kinases preceded proteolytic processing of
procaspase-3. It is possible that bpV(phen)-induced phos-
pho-JNK and/or phospho-p38 MAPK activate caspase-
3, which in turn initiate PC12 cell apoptosis. However,
due to the complexity and cross-talk among different
signaling pathways within a cell, further research is nec-
essary to elucidate this assumption.
CONCLUSIONS
In this study, the effects of peroxovanadium compound
bpV(phen) on PC12 cell survival have been examined.
BpV(phen) exerted a bimodal effect on PC12 cells: sur-
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vival-enhancing effect at lower and death-inducing ef-
fect at higher micromolar concentrations. We suggest
that the observed bpV(phen) actions might be associated
with modulation of MAPKs and caspase-3 activation.
Peroxovanadium compounds are potent insulinomi-
metic agents and PTP inhibitors. Stability and potency
of these complexes renders them attractive agents for
managing diabetes mellitus. However, the potentially
harmful effects of peroxovanadium compounds may ar-
gue against their use in clinics. A better understanding of
the molecular mechanism underlying vanadate toxicity
and the differences in the cellular response to vanadate
is required not only for the therapeutic use of peroxova-
nadium compounds in diabetes but also for their possi-
ble use as antineoplastic agents.
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SA@ETAK
Utjecaj razli~itih koncentracija peroksovanadijevog spoja bpV(phen)
na pre`ivljavanje PC12 stanica
Lada Rumora, Karmela Bari{i}, József Petrik i Tihana @ani} Grubi{i}
Spojevi peroksovanadija sna`ni su inzulinomimeti~ki agensi i inhibitori tirozinskih fosfataza. U ovom is-
tra`ivanju ispitivana je mogu}a toksi~nost peroksovanadijevoga kompleksa bpV(phen) na PC12 stanicama feo-
kromocitoma {takora te na~in na koji ovaj spoj utje~e na pre`ivljavanje i/ili umiranje stanica. BpV(phen) dvojako
je djelovao na PC12 stanice: primijenjen u ni`im mikromolarnim koncentracijama poticao je pre`ivljavanje sta-
nica, dok su vi{e mikromolarne koncentracije poticale umiranje stanica. 1 i 3 mol dm–3 bpV(phen) sna`no je
inducirao aktivaciju ERK kinaza. Suprotno tome, 10 i 100 mol dm–3 bpV(phen) stimulirao je sna`nu i dugo-
trajnu aktivaciju JNK i p38 MAPK kinaza te aktivaciju kaspaze-3, {to je prethodilo umiranju stanica procesom
apoptoze. Pretpostavlja se da bpV(phen) djeluje na pre`ivljavanje PC12 stanica na na~in da modulira aktivaciju
MAPK kinaza i kaspaze-3.
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